Plasma total homocysteine and cardiovascular risk in patients submitted to liver transplantation

Giampaolo Bianchi, Francesco Nicolino, Giorgia Passerini, Gian Luca Grazi, Paola Zappoli, Romina Graziani, Annalisa Berzigotti, Raffaela Chianese, Vilma Mantovani, Antonio Daniele Pinna, Marco Zoli – 28 December 2005 – Patients submitted to orthotopic liver transplantation (OLT) show an increased rate of cardiovascular events. OLT subjects have high homocysteine (Hcy) levels, but no data are available on the association of Hcy with cardiovascular events. In a cross‐sectional analysis, 230 subjects were studied at least 6 months after OLT (159 on cyclosporine, 71 on tacrolimus).

Recurrent hepatitis C posttransplant: Early preservation injury may predict poor outcome

Kymberly D.S. Watt, Elizabeth R. Lyden, James M. Gulizia, Timothy M. McCashland – 28 December 2005 – Organ cold/warm ischemia is thought to be a risk factor for increased severity of recurrence of hepatitis C (HCV) post liver transplantation. We had noted some HCV patients with preservation injury (PI) to have particularly poor outcomes. Our goal was to determine if PI on biopsy in HCV patients is associated with earlier, more rapidly progressive recurrence or graft and patient survival.

Parenteral nutrition–associated liver disease and the role for isolated intestine and intestine/liver transplantation

Alan L. Buchman, Kishore Iyer, Jonathan Fryer – 22 December 2005 – Parenteral nutrition–associated liver disease (PNALD) is the most devastating complication of long‐term parenteral nutrition therapy. Because its progression is typically insidious and its long‐term consequences are generally underappreciated, PNALD is often recognized too late, when liver injury is irreversible.

Systemic hemodynamics, vasoactive systems, and plasma volume in patients with severe Budd‐Chiari syndrome

Manuel Hernández‐Guerra, Eric López, Pablo Bellot, Carlos Piera, Juan Turnes, Juan G. Abraldes, Jaime Bosch, Juan C. García‐Pagán – 22 December 2005 – Budd‐Chiari syndrome (BCS) causes postsinusoidal portal hypertension, which leads to complications similar to those observed in cirrhosis. However, no studies have investigated whether patients with BCS develop the hyperdynamic circulatory syndrome present in patients with cirrhosis who have portal hypertension.

Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C

Yoshiaki Iwasaki, Hiroshi Ikeda, Yasuyuki Araki, Toshiya Osawa, Keiji Kita, Masaharu Ando, Toshinari Shimoe, Kouichi Takaguchi, Noriaki Hashimoto, Toshitsugu Kobatake, Minoru Tomita, Mitsuhiko Kawaguchi, Haruhiko Kobashi, Kohsaku Sakaguchi, Yasushi Shiratori – 22 December 2005 – In contrast to the United States, Japanese patients with chronic hepatitis C currently treated with interferon are generally 10 to 15 years older. Older patients, however, tend to experience more frequent adverse events.

Subscribe to